vancomycin has been researched along with surotomycin in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Citron, DM; Goldstein, EJ; Merriam, CV; Tyrrell, KL | 1 |
| Arya, A; Chuong, CL; Howland, KT; Kang, C; Li, T; Mascio, CT; Mortin, LI; Silverman, JA; Van Praagh, AD; Zhang, S | 1 |
| Bouillaut, L; Chesnel, L; Mascio, C; McBride, S; Schmidt, DJ; Sonenshein, AL; Sorg, JA; Suarez, JM; Tzipori, S | 1 |
| Cadnum, JL; Chan, L; Chesnel, L; Deshpande, A; Donskey, CJ; Gao, L; Hurless, K; Kundrapu, S; Polinkovsky, A | 1 |
| Alam, MJ; Bassères, E; Chesnel, L; Endres, BT; Garey, KW; Khaleduzzaman, M | 1 |
| Chesnel, L; Lee, CH; Louie, T; Mullane, KM; Patino, H; Rege, S; Stevens, C | 1 |
| Byrne, B; Cannon, K; Chesnel, L; Happe, J; Louie, T; Ward, L; Wu, K | 1 |
| Adedoyin, A; Chesnel, L; Daley, P; Guris, D; Jin, M; Khanna, S; Larson, KB; Louie, T; Lutz, JE; Murata, Y; Stoutenburgh, U | 1 |
| Boegli, L; Chesnel, L; deLancey Pulcini, E; Fisher, S; James, GA; Stewart, PS | 1 |
| Aldape, MJ; Bryant, AE; Field, KP; Rice, SN; Stevens, DL | 1 |
| Albert, E; Madhav, D; Mollie, J; Muhammad, A; Prateek, S; Rawish, F; Viveksandeep, TC | 1 |
1 review(s) available for vancomycin and surotomycin
| Article | Year |
|---|---|
Surotomycin (A Novel Cyclic Lipopeptide) vs. Vancomycin for the Treatment of Clostridioides difficile Infection: A Systematic Review and Meta-analysis.
Topics: Bias; Clostridium Infections; Humans; Lipopeptides; Peptides, Cyclic; Vancomycin | 2019 |
3 trial(s) available for vancomycin and surotomycin
| Article | Year |
|---|---|
Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Double-Blind Method; Female; Humans; Lipopeptides; Male; Middle Aged; Peptides, Cyclic; Recurrence; Treatment Outcome; Vancomycin | 2016 |
Enteric microbiome profiles during a randomized Phase 2 clinical trial of surotomycin versus vancomycin for the treatment of Clostridium difficile infection.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Bacterial Load; Bacteriological Techniques; Clostridium Infections; Double-Blind Method; Dysbiosis; Feces; Female; Gastrointestinal Microbiome; Humans; Lipopeptides; Male; Metagenomics; Middle Aged; Peptides, Cyclic; Real-Time Polymerase Chain Reaction; Time Factors; Vancomycin; Young Adult | 2017 |
Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridium Infections; Double-Blind Method; Humans; Lipopeptides; Middle Aged; Peptides, Cyclic; Placebos; Treatment Outcome; Vancomycin; Young Adult | 2017 |
7 other study(ies) available for vancomycin and surotomycin
| Article | Year |
|---|---|
In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Clostridioides difficile; Enterobacteriaceae; Enterobacteriaceae Infections; Enterocolitis, Pseudomembranous; Humans; Intestines; Lipopeptides; Metronidazole; Microbial Sensitivity Tests; Peptides, Cyclic; Vancomycin | 2012 |
In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile.
Topics: Animals; Anti-Bacterial Agents; Clostridioides difficile; Cricetinae; Enterocolitis, Pseudomembranous; Lipopeptides; Male; Mesocricetus; Microbial Sensitivity Tests; Peptides, Cyclic; Vancomycin | 2012 |
Effects of surotomycin on Clostridium difficile viability and toxin production in vitro.
Topics: Anti-Bacterial Agents; Bacterial Toxins; Cell Wall; Clostridioides difficile; Enterotoxins; Gene Expression Regulation, Bacterial; Lipopeptides; Metronidazole; Microbial Sensitivity Tests; Mutation; Peptides, Cyclic; Spores, Bacterial; Vancomycin; Virulence Factors | 2015 |
Effect of Surotomycin, a Novel Cyclic Lipopeptide Antibiotic, on Intestinal Colonization with Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice.
Topics: Animals; Anti-Bacterial Agents; Female; Gram-Negative Bacteria; Klebsiella pneumoniae; Lipopeptides; Metronidazole; Mice; Peptides, Cyclic; Vancomycin; Vancomycin Resistance; Vancomycin-Resistant Enterococci | 2016 |
Evaluating the Effects of Surotomycin Treatment on Clostridium difficile Toxin A and B Production, Immune Response, and Morphological Changes.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacterial Toxins; Caco-2 Cells; Cell Line, Tumor; Clostridioides difficile; Enterotoxins; Humans; Interleukin-8; Lipopeptides; Metronidazole; Microbial Sensitivity Tests; Microscopy, Electron, Scanning; Peptides, Cyclic; Vancomycin | 2016 |
Analysis of Clostridium difficile biofilms: imaging and antimicrobial treatment.
Topics: Aminoglycosides; Anti-Bacterial Agents; Biofilms; Biological Transport; Clostridioides difficile; Colony Count, Microbial; Fidaxomicin; Humans; Lipopeptides; Metronidazole; Microbial Sensitivity Tests; Microscopy, Electron, Scanning; Peptides, Cyclic; Spores, Bacterial; Vancomycin | 2018 |
Sub-lethal doses of surotomycin and vancomycin have similar effects on Clostridium difficile virulence factor production in vitro.
Topics: Anti-Bacterial Agents; Clostridioides difficile; Gene Expression Regulation, Bacterial; Lipopeptides; Microbial Sensitivity Tests; Peptides, Cyclic; Time Factors; Vancomycin; Virulence Factors | 2018 |